RESEARCH MONOGRAPH · KDC-MN-028

Pramiracetam

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

65/100

Most potent racetam by weight. Cholinergic mechanism is the differentiator

Pramiracetam is piracetam with a diisopropylaminoethyl group replacing the simple amide, developed by Parke-Davis in the late 1970s, and pharmacologically it's the most potent racetam by weight, often working at doses an order of magnitude lower than piracetam for comparable effects in animal models.

Mechanism is primarily cholinergic. The diisopropylaminoethyl substituent makes pramiracetam considerably more lipophilic than piracetam, with much better blood-brain barrier penetration, and the in-vivo effects center on increased high-affinity choline uptake in hippocampal and cortical synaptosomes. The Pugsley and Sastry papers from the early 1980s established this mechanism reasonably well, showing dose-dependent increases in cholinergic tone without direct effects on acetylcholine receptors themselves.

Importantly, the cholinergic effect of pramiracetam is upstream of the receptor, working at the level of choline transport, which makes the pharmacology distinct from cholinesterase inhibitors (like donepezil) or direct cholinergic agonists (like xanomeline). It increases the supply of acetylcholine without artificially boosting synaptic concentration in a way that drives receptor desensitization. That mechanistic feature is worth noting because it suggests the cholinergic tolerance profile should be cleaner than chronic AChEI administration, though this hasn't been tested rigorously in long-term studies.

Clinical evidence is genuinely thin. There was a small Parke-Davis program in the 1980s on cognitive impairment, but the compound never made it through to approval in the US, and most of the published clinical work is small, older, and methodologically limited. Animal cognitive enhancement data is more consistent (scopolamine-reversal, electroconvulsive shock learning impairment, age-related memory decline models), but human translation hasn't been rigorously demonstrated.

What's interesting as a research tool is the potency. If you want to study cholinergic mechanism with a small-molecule probe at low milligram doses, pramiracetam is more practical than higher-dose racetams. The metabolism is reasonable, the PK profile is well-documented in the older literature, and oral absorption is good.

Sourcing is okay. Multiple legitimate suppliers, but the more complex substitution pattern than piracetam means vendor quality varies more. HPLC and mass-spec verification is recommended. The compound is more expensive per gram than piracetam but considerably less than aniracetam due to simpler synthesis once you have the right intermediate.

Cholinergic-mechanism racetam with potency advantage, modest clinical evidence.

Evidence: 45
Mechanism: 70
Reliability: 65
Safety: 78
Sourcing: 75
Value: 70
Signal: 65
Staying power: 55

Plain-language summary Intrigue 55 / 100

Pramiracetam is a more potent piracetam analog with strong effects on hippocampal acetylcholine release. It is used in Italy for neurological disorders and is popular in nootropic communities for memory enhancement. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Diisopropylaminoethyl pyrrolidinone racetam

A high-affinity choline uptake potentiating racetam developed by Parke-Davis, characterized by stronger cholinergic activity than piracetam and approval in Eastern Europe for cognitive impairment.

Abstract

Pramiracetam (CI-879; N-[2-(diisopropylamino)ethyl]-2-oxo-1-pyrrolidineacetamide; CAS 68497-62-1; molecular formula C14H27N3O2; molecular weight 269.39) is a piracetam analog developed by Parke-Davis (now Pfizer) in the 1980s and marketed in Italy and Eastern Europe under names including Pramistar and Neupramir for cognitive impairment, dementia, and post-traumatic memory disorders. The structural modification from piracetam is replacement of the acetamide with a diisopropylaminoethyl amide, which substantially increases lipophilicity and produces a markedly different potency profile (effective doses are 5 to 10 times lower than equivalent piracetam doses). The principal mechanism is enhancement of high-affinity choline uptake into cortical synaptosomes, through an action distinct from the high-affinity choline transporter (HACT) Vmax modulation but resulting in increased acetylcholine synthesis under conditions of high cholinergic demand. The compound also produces modest improvements in cerebral blood flow in elderly subjects with vascular cognitive impairment. Pharmacokinetics: plasma half-life 4.5 to 6 hours; oral bioavailability is high; the compound is renally excreted with minimal hepatic metabolism. The research literature reports dose ranges of approximately 400 to 1200 mg. The clinical evidence base includes randomized trials in mild to moderate dementia, traumatic brain injury rehabilitation, and post-stroke cognitive impairment with consistent small-to-moderate effect sizes on attention and memory measures. The compound is not approved by the FDA but is sold as a research chemical in jurisdictions where it is not specifically scheduled.

Mechanism of action

Strong enhancement of high-affinity choline uptake; produces increased acetylcholine synthesis under high cholinergic demand. Modest cerebral blood flow improvement in vascular cognitive impairment.

Reported research dose ranges

Research literature reports a range of approximately 400 to 1200 mg.

References

Pugsley TA, et al. Pharmacology of pramiracetam. Neuropharmacology 1983.
Branconnier RJ, et al. The therapeutic efficacy of pramiracetam in Alzheimer's disease: preliminary observations. Psychopharmacol Bull 1983.
McLean A Jr, et al. Placebo-controlled study of pramiracetam in young males with memory and cognitive problems resulting from head injury and anoxia. Brain Inj 1991.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-028

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Pramiracetam

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs